CEO – Cann Group Limited, Chair – Medicinal Cannabis Industry Australia
Drawing on nearly three decades experience at global agribusiness Nufarm (ASX: NUF), and as the founding Chairman of MCIA, Cann Group’s CEO Peter Crock is shaping the future of the medicinal cannabis industry in Australia. With Peter at the helm and working closely with an experienced board of directors, Cann Group (ASX: CAN) received the first commercial cultivation licence in Australia, and was the first medicinal cannabis company to successfully list via an Initial Public Offering (IPO) on the Australian Securities Exchange (ASX), raising AUD$13.5 million.
To accelerate its growth, Cann Group has completed subsequent capital raisings totalling more than AUD$125m, which has enabled the advancement of its’ most ambitious project to date; a controlled environment, automated production facility which will be capable of producing up to 70,000kg of medicinal cannabis products per year when at full capacity.
With deep knowledge and experience in the areas of marketing, business and technology development, as well as mergers and acquisitions, Peter has overseen the growth and advancement of Cann Group.
In chairing the MCIA, Australia’s peak industry body for medicinal cannabis, Peter is well versed in the management of regulatory framework in both Australia, and abroad.
Executive Chairman & CEO MedReleaf Australia
Russell co-founded MedReleaf Australia with Nathan Davis in 2016 as a privately owned medicinal cannabis company.
He has 35 years success in pharmacy business ownership, management and innovation combined with experience in a number of other fields including pharmacy wholesaling to an 80 member group of pharmacist proprietors, property development, business mentoring, medical centre management and semi-professional sports coaching as an accredited AFLQ senior coach.
Elisabetta Faenza MAICD
CEO LeafCann Group
Elisabetta is an expert in relationship management, optimising individual, organisational and societal outcomes, facilitating collaboration and fundraising through win-win relationships. As Co-Founder and CEO of LeafCann Group, Elisabetta has driven the organisation’s strategic positioning as an industry leader. With her core team Elisabetta has expertly laid the groundwork for product development, acquiring critical infrastructure, and developing patenting, licensing and certification pathways. This has positioned LeafCann as a future operational centre of excellence for the emergent Medicinal Cannabis sector in Australasia and Europe.
Elisabetta is a Clinical Hypnotherapist and consultant hypnotherapist to medical and allied health practices including; pain management specialists, physiotherapists, and dentists. Elisabetta has extensive experience as a strategic planner and relationship manager for transnationals and NGOs in the health and regenerative agriculture sectors. Her experience in project planning, strategic partnerships and fundraising has allowed her to identify key strategic partners and negotiate joint venture agreements both nationally and internationally.
CEO and Managing Director, Epilepsy Action Australia
Carol’s extensive background spans more than 35 years in the not-for-profit human services sector. She has been at the forefront of the medical cannabis movement in Australia. In her role at Epilepsy Action she has had significant contact with people faced with managing very challenging forms of medication resistant epilepsy, with few or no conventional options left. Carol has seen the changes in people’s lives, including reduction in the severity and frequency of seizures, resulting from use of medicinal cannabis.